# The Effect of REcombinant Human Thrombopoietin (rhTPO) on Sepsis Patients With aCUte Severe thrombocytopEnia

> **NCT02707497** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Ruilan Wang** · enrollment: 200 (estimated)

## Conditions studied

- Sepsis
- Thrombocytopenia

## Interventions

- **DRUG:** rhTPO
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02707497
- **Lead sponsor:** Ruilan Wang
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-01
- **Primary completion:** 2024-08-31
- **Final completion:** 2024-09-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-04-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02707497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02707497, "The Effect of REcombinant Human Thrombopoietin (rhTPO) on Sepsis Patients With aCUte Severe thrombocytopEnia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02707497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*